PetMed Express (NASDAQ:PETS – Get Free Report) was upgraded by equities research analysts at Zacks Research to a “hold” rating in a note issued to investors on Thursday,Zacks.com reports.
PetMed Express Trading Up 2.7%
Shares of NASDAQ:PETS traded up $0.06 during midday trading on Thursday, hitting $2.30. The company had a trading volume of 61,275 shares, compared to its average volume of 78,884. PetMed Express has a 12 month low of $1.57 and a 12 month high of $4.32. The stock has a market cap of $49.22 million, a price-to-earnings ratio of -0.74 and a beta of 0.78. The firm has a fifty day simple moving average of $2.44 and a 200 day simple moving average of $2.66.
PetMed Express (NASDAQ:PETS – Get Free Report) last issued its quarterly earnings data on Thursday, February 5th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.44). The business had revenue of $40.66 million for the quarter, compared to analyst estimates of $54.04 million. PetMed Express had a negative return on equity of 70.81% and a negative net margin of 35.51%. Equities analysts forecast that PetMed Express will post -2.72 EPS for the current fiscal year.
Institutional Inflows and Outflows
About PetMed Express
PetMed Express, Inc operates as an online and catalog-based pet pharmacy and retail supplier under the 1-800-PetMeds brand name. The company distributes prescription and non‐prescription medications, nutritional supplements, flea and tick control products, and a range of pet health supplies directly to consumers. Through its licensed veterinary pharmacy in Delray Beach, Florida, PetMed Express fills orders for dogs, cats and other companion animals, offering both branded and generic products alongside its own private‐label formulations.
Founded in 1996 by Marc Puleo, PetMed Express built its business on the premise of convenience and cost savings for pet owners seeking reliable access to veterinary medications.
Recommended Stories
Receive News & Ratings for PetMed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express and related companies with MarketBeat.com's FREE daily email newsletter.
